Needham & Company LLC Reaffirms “Buy” Rating for Viridian Therapeutics (NASDAQ:VRDN)
Needham & Company LLC reiterated their buy rating on shares of Viridian Therapeutics (NASDAQ:VRDN – Free Report) in a research report released on Monday morning,Benzinga reports. They currently have a $38.00 price objective on the stock. Other equities research analysts have also issued reports about the company. TD Cowen started coverage on Viridian Therapeutics in […]
29 Nov 07:24 · The Markets Daily